93 related articles for article (PubMed ID: 12724012)
1. Proliferative activity in primary ovarian carcinoid tumors.
Resl M; Reslová T; Krejcí E; Vagunda V; Nakatani Y; Miyagi E; Bedrna J; Richter P; Vorísek K
Gynecol Endocrinol; 2003 Feb; 17(1):1-6. PubMed ID: 12724012
[TBL] [Abstract][Full Text] [Related]
2. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
3. Primary or secondary? Genotyping confirmation of an ovarian primary carcinoid tumor.
Dotto J; Mezzetti T; Hui P
Int J Gynecol Pathol; 2008 Jan; 27(1):33-6. PubMed ID: 18156971
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II-alpha in pulmonary carcinoid tumors.
Resl M; Simek J; Bukac J; Rothröckel P; Siller J
Pathol Res Pract; 2001; 197(3):169-73. PubMed ID: 11314780
[TBL] [Abstract][Full Text] [Related]
5. Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining.
Ludvíková M; Holubec L; Ryska A; Topolcan O
Anticancer Res; 2005; 25(3A):1835-40. PubMed ID: 16033110
[TBL] [Abstract][Full Text] [Related]
6. Ki67 Proliferative Index in Carcinoid Tumors Involving Ovary.
Zhang X; Jones A; Jenkins SM; Huang Y
Endocr Pathol; 2018 Mar; 29(1):43-48. PubMed ID: 29349725
[TBL] [Abstract][Full Text] [Related]
7. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
8. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
9. Ki-S1--a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy.
Kuropkat C; Rudolph P; Parwaresch R; Werner JA
Anticancer Res; 2003; 23(5A):3965-70. PubMed ID: 14666704
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Brustmann H
Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
[TBL] [Abstract][Full Text] [Related]
11. Typical thyroid-type carcinoma arising in struma ovarii: a report of 4 cases and review of the literature.
Roth LM; Miller AW; Talerman A
Int J Gynecol Pathol; 2008 Oct; 27(4):496-506. PubMed ID: 18753973
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of immunohistochemistry in gastric neuroendocrine (carcinoid) tumors.
Safatle-Ribeiro AV; Ribeiro U; Corbett CE; Iriya K; Kobata CH; Sakai P; Yagi OK; Pinto PE; Zilberstein B; Gama-Rodrigues J
Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):21-8. PubMed ID: 17206073
[TBL] [Abstract][Full Text] [Related]
13. Quantity of AgNORs in gastric endocrine carcinoid tumours as a potential prognostic tool.
Giuffrè G; Mormandi F; Barresi V; Bordi C; Tuccari G; Barresi G
Eur J Histochem; 2006; 50(1):45-50. PubMed ID: 16584984
[TBL] [Abstract][Full Text] [Related]
14. Primary ovarian trabecular carcinoid tumor: a case report and literature review.
Bai X; Li N; Wang F; Li S; Yu Q
Arch Gynecol Obstet; 2010 Oct; 282(4):407-11. PubMed ID: 20652280
[TBL] [Abstract][Full Text] [Related]
15. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 and DNA topoisomerase II alpha could be helpful for predicting long-term survival of patients with glioblastoma.
Ho DM; Hsu CY; Ting LT; Chiang H
Am J Clin Pathol; 2003 May; 119(5):715-22. PubMed ID: 12760291
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
18. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases.
Strosberg J; Nasir A; Cragun J; Gardner N; Kvols L
Gynecol Oncol; 2007 Jul; 106(1):65-8. PubMed ID: 17475313
[TBL] [Abstract][Full Text] [Related]
19. A 35-year retrospective study of carcinoid tumors in Taiwan: differences in distribution with a high probability of associated second primary malignancies.
Li AF; Hsu CY; Li A; Tai LC; Liang WY; Li WY; Tsay SH; Chen JY
Cancer; 2008 Jan; 112(2):274-83. PubMed ID: 18008361
[TBL] [Abstract][Full Text] [Related]
20. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
